Predictive Association of C3435T Genetic Polymorphism with the Efficacy or Safety of Lopinavir and Ritonavir in COVID-19 Patients

Overview

Journal Pharmacogenomics

Specialties Genetics
Pharmacology

Date 2021 Mar 24

PMID 33759544

Citations 2

Authors

Mohitosh Biswas

Affiliations

Soon will be listed here.

Abstract

Lopinavir and ritonavir are substrates of permeability glycoprotein encoded by The efficacy and safety of these drugs is unknown in COVID-19 patients affected by genetic variability. Patients carrying one or two copies of the C3435T were predictively considered as risk phenotypes. It was predicted that risk phenotypes due to carrying either one or two copies of C3435T were highly prevalent in Europe (76.8%; 95% CI: 75-78), followed by America (67%; 95% CI: 65-69), Asia (63.5%; 95% CI: 62-65) and Africa (41.4%; 95% CI: 37-46), respectively. It is hypothesized that a considerable proportion of COVID-19 patients treated with lopinavir/ritonavir inheriting C3435T genetic polymorphism may be predisposed to either therapeutic failure or toxicity.

Citing Articles

Genetic variability in the glucocorticoid pathway and treatment outcomes in hospitalized patients with COVID-19: a pilot study.

Stampar P, Blagus T, Goricar K, Bogovic P, Turel G, Strle F Front Pharmacol. 2024; 15:1418567.

PMID: 39135792 PMC: 11317398. DOI: 10.3389/fphar.2024.1418567.

Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.

Biswas M, Sawajan N, Rungrotmongkol T, Sanachai K, Ershadian M, Sukasem C Front Pharmacol. 2022; 13:835136.

PMID: 35250581 PMC: 8894812. DOI: 10.3389/fphar.2022.835136.

References

Sills G, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson E . Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia. 2005; 46(5):643-7. DOI: 10.1111/j.1528-1167.2005.46304.x. View

Park M, Her S, Kim C, SunCho J, Park G, Kim T . Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians. Genet Med. 2015; 18(8):833-41. DOI: 10.1038/gim.2015.171. View

Su J, Xu J, Li X, Zhang H, Hu J, Fang R . ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One. 2012; 7(10):e46366. PMC: 3467260. DOI: 10.1371/journal.pone.0046366. View

Calderon-Cruz B, Rodriguez-Galvan K, Manzo-Francisco L, Vargas-Alarcon G, Fragoso J, Pena-Duque M . C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention. Thromb Res. 2015; 136(5):894-8. DOI: 10.1016/j.thromres.2015.08.025. View

Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A . Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv. 2013; 6(11):1166-75. DOI: 10.1016/j.jcin.2013.06.010. View

Tang X, Wang J, Zhang J, Meng X, Xu B, Qiao S . Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol. 2012; 69(5):1103-12. DOI: 10.1007/s00228-012-1446-8. View

Baralic K, Jorgovanovic D, Zivancevic K, Miljakovic E, Antonijevic B, Djordjevic A . Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. Toxicol Appl Pharmacol. 2020; 406:115237. PMC: 7483129. DOI: 10.1016/j.taap.2020.115237. View

Luo M, Li J, Xu X, Sun X, Sheng W . ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis. Thromb Res. 2012; 129(6):754-9. DOI: 10.1016/j.thromres.2011.12.003. View

Tazzite A, Kassogue Y, Diakite B, Jouhadi H, Dehbi H, Benider A . Association between ABCB1 C3435T polymorphism and breast cancer risk: a Moroccan case-control study and meta-analysis. BMC Genet. 2016; 17(1):126. PMC: 5007843. DOI: 10.1186/s12863-016-0434-x. View

10.

Plumpton C, Roberts D, Pirmohamed M, Hughes D . A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. Pharmacoeconomics. 2016; 34(8):771-93. DOI: 10.1007/s40273-016-0397-9. View

11.

Tavares L, Marcatto L, Soares R, Krieger J, Pereira A, Santos P . Association Between Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients. Front Pharmacol. 2018; 9:542. PMC: 5975540. DOI: 10.3389/fphar.2018.00542. View

12.

Olagunju A, Schipani A, Siccardi M, Egan D, Khoo S, Back D . CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. Pharmacogenet Genomics. 2014; 24(9):459-63. DOI: 10.1097/FPC.0000000000000073. View

13.

Borse M, Dong O, Polasek M, Farley J, Stouffer G, Lee C . CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. Pharmacogenomics. 2017; 18(12):1155-1166. DOI: 10.2217/pgs-2017-0075. View

14.

Kim D, Kim M, Lee S, Kang R, Lee S . Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure. 2006; 15(5):344-7. DOI: 10.1016/j.seizure.2006.02.015. View

15.

Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

16.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

17.

Juurlink D . Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020; 192(17):E450-E453. PMC: 7207200. DOI: 10.1503/cmaj.200528. View

18.

Bellusci C, Rocco C, Aulicino P, Mecikovsky D, Curras V, Hegoburu S . Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children. Gene. 2013; 522(1):96-101. DOI: 10.1016/j.gene.2013.03.020. View

19.

Liu X, Ma Q, Zhao Y, Mu W, Sun X, Cheng Y . Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus. Pharmacotherapy. 2017; 37(9):1073-1080. PMC: 5600689. DOI: 10.1002/phar.1988. View

20.

Mahdieh N, Rabbani A, Firouzi A, Zahedmehr A, Hoseinimoghaddam M, Saedi S . Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention. Cardiovasc Toxicol. 2018; 18(5):482-491. DOI: 10.1007/s12012-018-9459-x. View